The medium term case for EMD is supported by relative valuations in the HY segment, bottoming of fundamentals, and abundant global liquidity. However, health risks are still elevated around the discoveries of new and more contagious virus variants in South Africa and the UK that have forced re-introduction of tightening measures globally. READ MORE
Similar Posts:
- COVID Surge Puts Brakes on Thai and Malaysia Growth: Survey (Nikkei Asia)
- Asian Tigers: South Korea and Taiwan (Franklin Templeton)
- Three Reasons We Remain Bullish on Emerging Markets Long Term (Franklin Templeton)
- South Africa’s Economic and Potential Downgrade Woes (Bloomberg)
- MENA Equities: Five Key Themes and Reasons for Optimism (Franklin Templeton)
- In Long Term Absolute Return Portfolio, I Have About 20 Stocks Which are Still Dominantly India: Chris Wood (The Economic Times)
- Five-Year Capital Market Outlook: Asia (Willis Towers Watson)
- Emerging Market Fixed Income: 2019 Outlook (UBP)
- Deutsche Bank: Emerging Market Rally is a False Dawn (Barron’s)
- Where to Find Opportunities in Emerging Markets (BlackRock)
- 3 Ways to Structure an Emerging Markets Portfolio (Barron’s)
- The Tailwinds Have Arrived: Our 2018 Outlook for Emerging Markets (Hermes Investment Management)
- International Stock Outlook: Global Recovery (Fidelity International)
- S&P Global Warns of Ratings Downgrade if South Africa Doesn’t Rebound (Business Report)
- EMD Outlook 2018: Robust Global Growth Lifts Emerging Markets (NNIP)
